The therapeutic effect of lithium in bipolar affective disorder may be connected with decreasing intracellular Ca 2+ concentrations. Several linkage studies have identified a potential bipolar affective disorder susceptibility locus within chromosomal region 21q22.3. This locus contains two genes expressed in the brain -ADARB1 and TRPM2 -involved in regulating intracellular Ca 2+ concentrations. The aim of this study was an identification of mutations in the coding sequences of ADARB1 and TRPM2 and their association with bipolar affective disorder. For that purpose we screened 60 patients with bipolar affective disorder and a control group of 66 subjects using single strand conformation polymorphism and sequence analysis. For rapid screening we performed restriction fragment length polymorphism analysis. Screening of bipolar affective disorder patients for mutations in TRPM2 led to identification of three novel and four known transitions. Two transitions resulted in the substitutions: R755C and A890V. Screening of the coding sequence of ADARB1 did not reveal any mutations except one already known transition. A comparison of the transition frequency in patients and controls does not support association of the detected mutations with bipolar affective disorder. According to our results, bipolar affective disorder may not be caused by mutations in ADARB1. However, this study does not exclude TRPM2 as a candidate gene since we have screened only about 30 per cent of the entire coding sequence of this large gene.
INTRODUCTION
Lithium, commonly used in the therapy of bipolar affective disorder (BPAD), decreases intracellular Ca 2+ mobilisation (Iconomov et al., 1999) . This observation led to the conclusion that high intracellular Ca 2+ levels in neurones possibly due to mutations affecting the gene(s) responsible for Ca 2+ signalling may contribute to the pathogenesis of BPAD. According to findings of Straub et al. (1994) , confirmed later by different authors (DeteraWadleigh et al., 1996; Vallada et al., 1996; Smyth et al., 1997; Aita et al., 1999) , the susceptibility locus for BPAD may be present in the chromosomal region 21q22.3. There are two genes involved in the neuronal Ca 2+ signalling -ADARB1 and TRPM2 -that map to this region. ADARB1, alternatively named ADAR2 is expressed mainly in the brain, lungs and kidneys (Villard et al., 1997; Mittaz et al., 1997) . The gene encodes an RNA editase (hRED1) whose function is editing of the pre-mRNA for glutamate receptor subunit B (GluR-B), by site-selective adenosine deamination. The GluR-B premRNA editing at two adenosine residues results in amino acid changes that alter Ca 2+ permeability of the glutamate AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-responsive receptor (Melcher et al., 1995) .
A. Kostyrko and others TRPM2, previously termed LTRPC2 or TRPC7 (Nagamine et al., 1998) , is expressed in the brain, lymphocytes, and human pancreatic islets (Qian et al., 2002) . TRPM2 protein (transient receptor potential cation channel subfamily M, member 2) is linked to the phosphatidylinositol signal transduction pathway that causes Ca 2+ influx into the cell (Clapham et al., 2001) . Its specific function associated with cell death is not entirely clear (Hara et al., 2002) . TRPM2 acts as a storage-operated calcium channel activated by intracellular Ca 2+ depletion. The protein consists of six transmembrane domains (with the Ca 2+ entry site located between the fifth and the sixth domain) and a large cytosolic, alternatively spliced domain, containing 80% of the protein sequence. Ca 2+ entry into the cell requires intracellular ADP-ribose (Perraud et al., 2001 ) and provides positive feedback for activation of the channel (McHugh et al., 2003) . The results of linkage studies and evidence for an altered Ca 2+ homeostasis in lymphocytes of the patients with BPAD (Yoon et al., 2001 ) made these genes candidates for the causative agent of the disorder. To date, however, there is no evidence for ADARB1 or TRPM2 mutations in BPAD or any other disease.
The aim of the study was to detect mutations and/or polymorphisms in these genes and compare their frequencies in BPAD patients and in the healthy subjects. We screened the ADARB1 coding sequence and exons of TRPM2 that encode a putative transmembrane and a catalytic domain of the TRPM2 Ca 2+ channel.
MATERIALS AND METHODS
Subjects included in the study (n = 60) were unrelated patients with bipolar affective disorder diagnosed according to DSM-IV criteria and treated in the Department of Adult Psychiatry, University of Medical Sciences in Poznan (Poland). The control group consisted of 66 healthy persons. The Local Ethics Committee approved the study, and a written consent of all patients was obtained.
Single strand conformation polymorphism (SSCP). Genomic DNA was isolated from peripheral blood lymphocytes by a standard salt-out method. The amplification was conducted under standard conditions with annealing temperatures varying from 59.5 o C to 63.8 o C. Denatured PCR fragments were analysed by SSCP on 8% polyacrylamide gel with silver staining.
Sequencing. The PCR products showing altered migration were purified on 1.5% agarose gel and subjected to direct sequencing with the use of specific Cy5-labelled dideoxy nucleotides (Thermo Sequenase Cy5 Dye Termination Kit, Amersham Biosciences) or Cy5-labelled primers (AmpliCycle Sequencing Kit, Applied Biosystems). The sequenced fragments were analysed on an ALFexpress sequencer (Amersham-Pharmacia Biotech).
Restriction fragment length polymorphism (RFLP). For rapid detection of the c.2769C>T transition in the control group, digestion of 185-base pair (bp) PCR products with the MslI restriction endonuclease (New England Biolabs) was carried out at 37 o C for 16 h. The digested PCR products harbouring the c.2769C>T transition showed two bands (111 bp and 53 bp) on 3% agarose gel.
RESULTS AND DISCUSSION
With the use of SSCP and sequence analysis we detected one known heterozygous transition -c.2234A>G in the coding sequence of ADARB1 (GenBank mRNA BC065545.1). This transition resulted in synonymous substitution K694K. Four known: c.2363C>T, c.2890 +55 A>G, c.3246 +68 C>T, c.3205C>T and three novel: c.2421 +23 C>T (ss49785911), c.2769C>T (ss49785909), c.3010C>T (ss49785910) transitions were detected in the coding sequence of TRPM2 (GeneBank mRNA NM_003307). The c.2363C>T transition resulted in the substitution R755C while the c.2769C>T transition resulted in the A890V substitution. The c.3010C>T and the c.3205C>T transitions resulted in the synonymous substitutions A970A and F1035F, respectively. The other transitions: c.2421 +23 C>T, c.2890 +55 G>A and c.3246 +68 C>T were intronic substitutions. We compared the frequency of the transitions in BPAD patients and controls but the difference was statistically insignificant. The highest χ 2 values were: 1.96 for c.2234G>A in ADARB1 and 1.02 for c.3205C>T in TRPM2 (Table 1) .
We screened the coding sequence of ADARB1 comprising 10 exons, and part (13 of 32 exons) of the TRPM2 sequence which encodes a putative transmembrane domain with the channel pore (permeable to Ca 2+ ) as well as a catalytic region (involved in ADP-ribose hydrolysis) containing a highly conserved NUDIX domain. We detected three novel c.C>T transitions in TRPM2 and one of them (c.2769C>T) led to a rare substitution A890V. However, our findings do not support an association of the transitions with the disorder.
The role of TRPM2 as a candidate gene was confirmed by the recent finding of three single nu-
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cleotide polymorphisms strongly associated with BPAD (McQuillin et al., 2006; Xiu et al., 2006) . It also remains possible that in some families BPAD is associated with an as yet unknown mutation(s) in TRPM2. As TRPM2 is expressed also in pancreatic islets (Qian et al., 2002) some mutations could affect not only neuronal but also pancreatic Ca 2+ homeostasis. Bipolar disorder often coincides with type 2 diabetes (Regenold et al., 2002) , which may appear as a result of an altered pancreatic intracellular Ca 2+ homeostasis. Further screening of patients affected with both diseases for mutations in the TRPM2 coding sequence might help to resolve this problem. 
